Post-prandial Glycaemic Controlling Effects of BSG in Singapore Adults With Metabolic Syndrome
Primary Purpose
Metabolic Syndrome, Diabetes, Diet Modification
Status
Recruiting
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
autoclaved BSG-containing biscuits
bio-transformed BSG-containing biscuits
control biscuits
Sponsored by
About this trial
This is an interventional prevention trial for Metabolic Syndrome focused on measuring Metabolic Syndrome, middle-aged and older adults, Post-prandial Glycaemic response, bio-transformed food
Eligibility Criteria
Inclusion Criteria:
- Male and female participants, aged 35-85 years old
- English-literate and able to give informed consent in English
- Willing to follow the study procedures
- Meet any 3 of the 5 following NCEP-ATP III MetS criteria: waist circumference > 102 cm (male), > 88 cm (female) (For Asian population: Waist circumference > 90 cm (male), > 80 cm (female)); fasting glucose concentration ≥ 100 mg/dL or on medication; triglyceride ≥ 150 mg/dL or on medication; high density lipoprotein cholesterol (HDL) < 40 mg/dL (male), < 50 mg/dL (female); systolic or diastolic blood pressure > 130/85 mmHg or on medication);
Exclusion Criteria:
- Significant change in weight (≥ 3 kg body weight) during the past 3 months
- Allergy to barley, wheat, corn, egg, or other ingredients found inside the biscuits.
- Acute illness at the study baseline
- Exercising vigorously* over the past 3 months. *Defined as having > 6 metabolic equivalents of exercise daily; approximately 20 mins of moderate intensity exercise (e.g. slow jogging) a day
- Following any restricted diet (e.g. vegetarian)
- Smoking
- Have a daily intake of more than 2 alcoholic drinks per day
- Taking dietary supplements or food which may impact the outcome of interests (e.g. fermented foods, probiotic supplement etc.)
- Consumption of antibiotics over past 3 months.
- Pregnant, lactating, or planning pregnancy in the next 6 months
- Insufficient venous access to allow the blood collection
- Prescribed and taking antihypertensive/cholesterol-lowering/ type-2 diabetic medication which started less than 3 years prior to the intervention participation
- High current intake of fibre* from brown rice or wholemeal products. *High, moderate or low intake taken as ≥ 6 servings, 4 - 5 servings, and ≤ 3 servings daily respectively based on My Healthy Plate guidelines
- High current intake of fibre* from vegetables. * High, moderate or low intake taken as ≥ 2 servings, 2 servings, and ≤ 1 serving respectively based on My Healthy Plate guidelines
Sites / Locations
- Yujing XuRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
Control biscuits group
autoclaved BSG-containing group
bio-transformed BSG-containing group
Arm Description
For each MTT, subjects are to consume 90 g control biscuits as their breakfast within 15 mins.
For each MTT, subjects are to consume 90 g autoclaved BSG-containing biscuits as their breakfast within 15 mins.
For each MTT, subjects are to consume 90 g bio-transformed BSG-containing biscuits as their breakfast within 15 mins.
Outcomes
Primary Outcome Measures
Change in blood glucose concentration
Glucose concentration in the blood will be measured
Change in blood insulin concentration
Insulin concentration in the blood will be measured
Change in blood triglyceride concentration
Triglyceride concentration in the blood will be measured
Change in blood cholesterol concentration
Total cholesterol concentration in the blood will be measured
Change in blood Low-density Lipoprotein-cholesterol (LDL) concentration
Low-density Lipoprotein-cholesterol concentration in the blood will be measured
Change in High-density Lipoprotein-cholesterol (HDL) concentration
High-density Lipoprotein-cholesterol concentration in the blood will be measured
Change in blood amino acid concentration
Amino acid concentration in the blood will be measured
Secondary Outcome Measures
Change in appetite assessed by visual analogue scale
Visual analogue scale will be used to assess appetite.
Change in breath CH4 and H2 concentrations
CH4 and H2 concentrations will be measured by breath analyzer
Change in weight and height
Weight (in kilograms) and height (in meters) will be combined to report BMI in kg/m^2
Change in waist circumference
Waist circumference (in cm) will be measured
Change in blood pressure
Systolic and diastolic blood pressure (in mmHg) will be measured by a blood pressure monitor.
Full Information
NCT ID
NCT05421780
First Posted
May 30, 2022
Last Updated
September 28, 2022
Sponsor
National University of Singapore
Collaborators
Ministry of Education, Singapore
1. Study Identification
Unique Protocol Identification Number
NCT05421780
Brief Title
Post-prandial Glycaemic Controlling Effects of BSG in Singapore Adults With Metabolic Syndrome
Official Title
Impact of Brewer's Spent Grain (BSG) and Bio-transformed BSG Biscuits on Post-prandial Glycaemic Controlling Effects in Singapore Adults With Metabolic Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 29, 2022 (Actual)
Primary Completion Date
October 2022 (Anticipated)
Study Completion Date
May 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National University of Singapore
Collaborators
Ministry of Education, Singapore
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The purpose of this study is to assess the glycaemic controlling effects of BSG and bio-transformed BSG-containing biscuits in Singapore adults with MetS. The investigators hypothesized that consumption of BSG and bio-transformed BSG containing biscuit will improve glycaemic control.
Detailed Description
This is a double-blind, randomised, crossover experiment. During the 3-week, 19 subjects will participate in a 3 meal tolerance test (MTT). During each MTT session, all subjects are required to consume 90 g biscuits (either control, autoclaved BSG or bio-transformed BSG biscuits) and monitored over a period of 240 minutes. All three types of biscuits will be consumed at a randomised sequence during this 3-week period. Post-prandial blood glucose, insulin, lipid and amino acid responses, breath analysis, body composition, blood pressure, appetite assessment, and any other glycaemic biomarkers will be assessed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Diabetes, Diet Modification
Keywords
Metabolic Syndrome, middle-aged and older adults, Post-prandial Glycaemic response, bio-transformed food
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
19 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control biscuits group
Arm Type
Placebo Comparator
Arm Description
For each MTT, subjects are to consume 90 g control biscuits as their breakfast within 15 mins.
Arm Title
autoclaved BSG-containing group
Arm Type
Experimental
Arm Description
For each MTT, subjects are to consume 90 g autoclaved BSG-containing biscuits as their breakfast within 15 mins.
Arm Title
bio-transformed BSG-containing group
Arm Type
Experimental
Arm Description
For each MTT, subjects are to consume 90 g bio-transformed BSG-containing biscuits as their breakfast within 15 mins.
Intervention Type
Dietary Supplement
Intervention Name(s)
autoclaved BSG-containing biscuits
Intervention Description
Consumption of autoclaved BSG-containing biscuits as breakfast.
Intervention Type
Dietary Supplement
Intervention Name(s)
bio-transformed BSG-containing biscuits
Intervention Description
Consumption of bio-transformed BSG-containing biscuits as breakfast.
Intervention Type
Dietary Supplement
Intervention Name(s)
control biscuits
Intervention Description
Consumption of plain biscuits as breakfast.
Primary Outcome Measure Information:
Title
Change in blood glucose concentration
Description
Glucose concentration in the blood will be measured
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in blood insulin concentration
Description
Insulin concentration in the blood will be measured
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in blood triglyceride concentration
Description
Triglyceride concentration in the blood will be measured
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in blood cholesterol concentration
Description
Total cholesterol concentration in the blood will be measured
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in blood Low-density Lipoprotein-cholesterol (LDL) concentration
Description
Low-density Lipoprotein-cholesterol concentration in the blood will be measured
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in High-density Lipoprotein-cholesterol (HDL) concentration
Description
High-density Lipoprotein-cholesterol concentration in the blood will be measured
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in blood amino acid concentration
Description
Amino acid concentration in the blood will be measured
Time Frame
Every week (week 1, week 2 and week 3)
Secondary Outcome Measure Information:
Title
Change in appetite assessed by visual analogue scale
Description
Visual analogue scale will be used to assess appetite.
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in breath CH4 and H2 concentrations
Description
CH4 and H2 concentrations will be measured by breath analyzer
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in weight and height
Description
Weight (in kilograms) and height (in meters) will be combined to report BMI in kg/m^2
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in waist circumference
Description
Waist circumference (in cm) will be measured
Time Frame
Every week (week 1, week 2 and week 3)
Title
Change in blood pressure
Description
Systolic and diastolic blood pressure (in mmHg) will be measured by a blood pressure monitor.
Time Frame
Every week (week 1, week 2 and week 3)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female participants, aged 35-85 years old
English-literate and able to give informed consent in English
Willing to follow the study procedures
Meet any 3 of the 5 following NCEP-ATP III MetS criteria: waist circumference > 102 cm (male), > 88 cm (female) (For Asian population: Waist circumference > 90 cm (male), > 80 cm (female)); fasting glucose concentration ≥ 100 mg/dL or on medication; triglyceride ≥ 150 mg/dL or on medication; high density lipoprotein cholesterol (HDL) < 40 mg/dL (male), < 50 mg/dL (female); systolic or diastolic blood pressure > 130/85 mmHg or on medication);
Exclusion Criteria:
Significant change in weight (≥ 3 kg body weight) during the past 3 months
Allergy to barley, wheat, corn, egg, or other ingredients found inside the biscuits.
Acute illness at the study baseline
Exercising vigorously* over the past 3 months. *Defined as having > 6 metabolic equivalents of exercise daily; approximately 20 mins of moderate intensity exercise (e.g. slow jogging) a day
Following any restricted diet (e.g. vegetarian)
Smoking
Have a daily intake of more than 2 alcoholic drinks per day
Taking dietary supplements or food which may impact the outcome of interests (e.g. fermented foods, probiotic supplement etc.)
Consumption of antibiotics over past 3 months.
Pregnant, lactating, or planning pregnancy in the next 6 months
Insufficient venous access to allow the blood collection
Prescribed and taking antihypertensive/cholesterol-lowering/ type-2 diabetic medication which started less than 3 years prior to the intervention participation
High current intake of fibre* from brown rice or wholemeal products. *High, moderate or low intake taken as ≥ 6 servings, 4 - 5 servings, and ≤ 3 servings daily respectively based on My Healthy Plate guidelines
High current intake of fibre* from vegetables. * High, moderate or low intake taken as ≥ 2 servings, 2 servings, and ≤ 1 serving respectively based on My Healthy Plate guidelines
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yujing Xu
Phone
98853979
Email
e0554129@u.nus.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jung Eun Kim
Organizational Affiliation
Food Science and technology, Faculty of Science, National University of Singapore
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yujing Xu
City
Singapore
ZIP/Postal Code
117543
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
yujing xu
Phone
98853979
Email
e0554129@u.nus.edu
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Electronic copies of the data with identifiable participant information will be kept on a secure website with access limited to Dr. Kim and Dr. Kim's research staff. All data will be de-identified prior to statistical analyses.
Learn more about this trial
Post-prandial Glycaemic Controlling Effects of BSG in Singapore Adults With Metabolic Syndrome
We'll reach out to this number within 24 hrs